The Hong Kong Monetary Authority has detailed its enhanced oversight framework for key retail payment systems, designating networks like Visa, Mastercard, and UnionPay for direct supervision to ensure security and stability in the city's rapidly digitizing economy.
GameStop's stock jumped nearly 5% Friday after the company announced plans for a billion-dollar acquisition, described by CEO Ryan Cohen as a potentially 'transformational' move for the retailer and the markets.
Facing a significant stock decline and a challenging Medicare Advantage outlook, UnitedHealth Group announces leadership changes and a 'Back to Basics' operational reset, aiming to stabilize its core business amid shifting market dynamics.
Venture capital titans Marc Andreessen and Ben Horowitz lead a massive $50.8 million fundraising effort for a new super PAC, 'Leading the Future,' aiming to shape AI-friendly policies in the 2026 elections.
Nikolay Storonsky, the billionaire CEO of fintech giant Revolut, has officially corrected corporate records to reaffirm his UK residency, following a brief filing that listed him in the UAE—a move that had sent shockwaves through regulators and political circles.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Zions Bancorporation has authorized a new $75 million stock repurchase program, a move analysts see as a bet on its undervalued shares and a commitment to shareholder returns as regional banks navigate a cautious regulatory environment.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Robinhood Markets is navigating a transformative phase, reportedly in talks to manage a potential federal 'Trump account' program for minors while simultaneously expanding into tokenized equities and prediction markets. This strategic shift raises critical questions about its regulatory footprint, business model evolution, and long-term valuation.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
TAL Education Group's stock soared following robust Q3 FY2026 results and a new share repurchase program, marking a potential inflection point for the Chinese tutoring giant navigating a post-regulatory landscape. Analysts debate if the rally signals a lasting recovery or a temporary reprieve.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
A pivotal week for prediction markets saw Coinbase partner with Kalshi to offer event contracts nationwide, while the CFTC moved to establish clearer regulatory standards. Meanwhile, traders sharply increased bets on a potential U.S. government shutdown.
Despite significant institutional purchases and regulatory progress, Bitcoin continues to drift lower, leading analysts and investors to question what price level will finally stem the tide.
As speculation intensifies over a potential acquisition of Warner Bros. Discovery by Netflix, short sellers are rapidly retreating from the stock, signaling market confidence in both the deal's completion and regulatory approval.
Canadian National CEO Tracy Robinson has delivered a stark assessment of the proposed Union Pacific-Norfolk Southern merger, stating the railroads have "a long way to go" to satisfy regulatory concerns. In CN's earnings call, she criticized the application for failing to address competitive harms and warned of impacts on shippers, setting the stage for a contentious review process.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
Reports suggest Elon Musk is exploring a merger between Tesla and SpaceX as the EV maker pivots to AI, while Chinese automakers gain record European market share and regulatory battles intensify.
